TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06317662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV
Study: NCT04800705

Intervention type: OTHER
Intervention: ultrasound assessment
Description: Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)

Intervention type: OTHER
Intervention: ultrasound assessment
Description: Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
Study: NCT05627960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-01 Compound
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-01 Compound
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-01 Compound
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-01 Compound
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-01 Compound
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.
Study: NCT05241106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYML-122
Description: each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
Study: NCT05773963

Intervention type: DEVICE
Group type: OTHER
Intervention: Irilens; Iridina; Afomill Lubricating Eye Drops
Description: * Irilens (with 0.4% HA as key ingredient);~* Iridina (with 0.4% HA as key ingredient);~* Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile).
Study: NCT04953546

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observation study, with no intervention
Study: NCT05131646

Intervention type: DRUG
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101

Intervention type: DRUG
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101

Intervention type: DRUG
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO or NG or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study: NCT04907656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBT
Description: As per arm of the same name
Study: NCT04905797

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
Study: NCT06317662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study: NCT04826107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment
Description: DP303c injection, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment（second-line of HER2-positive）
Description: DP303c injection, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment （third-line of HER2-positive）
Description: DP303c injection, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment（≥second-line of HER2 low expressing）
Description: DP303c injection, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c + PD-1/PD-L1 treatment
Description: DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
Study: NCT05662280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Intermittent Theta Burst Stimulation
Description: Standard iTBS protocol with active coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Intermittent Theta Burst Stimulation
Description: Standard iTBS protocol with active coil
Study: NCT05195437

Intervention type: OTHER
Intervention: QoLiSSY and PedsQL 4.0 questionnaires
Description: Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy.
Study: NCT05611645

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiotherapy
Description: Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
Study: NCT06451692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical pharmacist
Description: The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
Study: NCT06051318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast A
Description: Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast B
Description: Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
Study: NCT05721352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Nature scene plus heart rate variability biofeedback phone application
Description: phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study: NCT05151692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.
Study: NCT04905797

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry

Intervention type: OTHER
Intervention: World Health Organizations Disability Assessment Schedule (WHODAS 2.0)
Description: Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
Study: NCT05302167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Molehill Mountain app
Description: The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molehill Mountain app
Description: As above.
Study: NCT05614609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Comparing lidocaine spray and muscle relaxing medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Comparing lidocaine spray and muscle relaxing medication
Study: NCT05591859

Intervention type: DEVICE
Group type: OTHER
Intervention: Restoration Anatomic Acetabular Shell
Description: Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
Study: NCT06401694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-delivered meals
Description: Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-delivered meals
Description: Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness check and socialization visit
Description: At-home delivery with opportunity for driver observation and interaction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness check and socialization visit
Description: At-home delivery with opportunity for driver observation and interaction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker calls
Description: Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental grocery bag
Description: Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
Study: NCT06402955

Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: Radiotracer for imaging.

Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: Radiotracer for imaging.

Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: Radiotracer for imaging.

Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: Radiotracer for imaging.
Study: NCT06435416

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04905797

Intervention type: OTHER
Intervention: World Health Organizations Disability Assessment Schedule (WHODAS 2.0)
Description: Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.

Intervention type: OTHER
Intervention: World Health Organizations Disability Assessment Schedule (WHODAS 2.0)
Description: Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.

Intervention type: OTHER
Intervention: World Health Organizations Disability Assessment Schedule (WHODAS 2.0)
Description: Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05681351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Administered as SC injection.
Study: NCT05673200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT05673200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study: NCT04905797

Intervention type: DIAGNOSTIC_TEST
Intervention: Personality Inventory for DSM-5 (PID-5)
Description: Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Personality Inventory for DSM-5 (PID-5)
Description: Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
Study: NCT05673200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05673200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT06534125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo self-administered acupressure therapy to planned pressure points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy with acupuncture needles applied to planned pressure points

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Receive SOC AI therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Receive SOC AI therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibition Therapy
Description: Receive SOC AI therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04915183

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.